BRIEF-AN2 Therapeutics Announces Research Collaboration With GSK

Reuters11-10

BRIEF-AN2 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Research Collaboration With GSK

Nov 10 (Reuters) - AN2 Therapeutics Inc ANTX.O:

AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)
AN2 THERAPEUTICS: GATES FOUNDATION WILL PROVIDE THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN COLLABORATION

Source text: ID:nBwb9X3F1a

Further company coverage: ANTX.O

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582774873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582774873","market":"us","top_or_hot":-1,"title":"BRIEF-AN2 Therapeutics Announces Research Collaboration With GSK","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Research Collaboration With GSK</title></head><body><p><span>Nov 10 (Reuters)</span><span> - </span>AN2 Therapeutics Inc <span>ANTX.O</span>:</p><ul><li><p>AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)</p></li><li><p>AN2 THERAPEUTICS: GATES FOUNDATION WILL PROVIDE THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN COLLABORATION</p></li></ul><p>Source text: <span>ID:nBwb9X3F1a</span></p><p>Further company coverage: <span>ANTX.O</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-AN2 Therapeutics Announces Research Collaboration With GSK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-AN2 Therapeutics Announces Research Collaboration With GSK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Research Collaboration With GSK</title></head><body><p><span>Nov 10 (Reuters)</span><span> - </span>AN2 Therapeutics Inc <span>ANTX.O</span>:</p><ul><li><p>AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)</p></li><li><p>AN2 THERAPEUTICS: GATES FOUNDATION WILL PROVIDE THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN COLLABORATION</p></li></ul><p>Source text: <span>ID:nBwb9X3F1a</span></p><p>Further company coverage: <span>ANTX.O</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANTX","symbol_name":"AN2 Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA8Q5PGQ:1","article_id":"2582774873","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582774873","pubTimestamp":1762776559,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-AN2 Therapeutics Announces Research Collaboration With GSKNov 10 (Reuters) - AN2 Therapeutics Inc ANTX.O:AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANTX":"AN2 Therapeutics, Inc.","BK4007":"制药"},"translate_title":"BRIEF-AN2 Therapeutics宣布与GSK开展研究合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANTX":0.9},"content_text":"BRIEF-AN2 Therapeutics Announces Research Collaboration With GSKNov 10 (Reuters) - AN2 Therapeutics Inc ANTX.O:AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)AN2 THERAPEUTICS: GATES FOUNDATION WILL PROVIDE THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN COLLABORATIONSource text: ID:nBwb9X3F1aFurther company coverage: ANTX.O ((reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582774873","isCrawlerRequest":true}